Children’s Cancer Institute welcomes significant state-wide investment into paediatric research
February 24, 2015
Children’s Cancer Institute is delighted to be one of three recipients of a ground-breaking investment by the state government into paediatric medical research.
NSW Minister for Health, the Hon Jillian Skinner MP announced today that the state government will make a multi-million dollar investment into paediatric research and clinical care in NSW, to expand, integrate and improve paediatric research facilities across the state – including Children’s Cancer Institute, Children’s Medical Research Institute (CMRI) and Sydney Children’s Hospitals Network.
As part of this investment, Children’s Cancer Institute will receive a $6 million funding allocation towards infrastructure development and critical equipment to strengthen its capacity for vital medical research into childhood cancer.
Children’s Cancer Institute’s Executive Director, Professor Michelle Haber AM, is thrilled with the Health Minister’s announcement.
“We are overjoyed to see such a strong commitment from the state government to paediatric research,” she said today. “This funding will change the landscape of paediatric research in NSW and enhance the collaborations between world-class laboratory researchers and clinicians.
“This investment will provide Children’s Cancer Institute with vital equipment and increased space to accommodate more scientists, which will significantly build our research capabilities.
“Recent advances in technology and particularly genetics have made it possible for us to develop ground-breaking new approaches to find a cure for children with cancer whose chances of survival are otherwise dismal. The funding from the state government will bring us significantly closer to achieving this.”
About Children’s Cancer Institute
Originally founded by two fathers of children with cancer in 1976, Children’s Cancer Institute is the only independent medical research institute in Australia wholly dedicated to research into the causes, prevention and cure of childhood cancer. Forty years on, our vision remains unchanged – to save the lives of all children with cancer and to eliminate their suffering. The Institute has grown to now employ more than 220 researchers, operational staff and students, and has established a national and international reputation for scientific excellence.
Our focus is on translational research, and we have an integrated team of laboratory researchers and clinician scientists who work together in partnership to discover new treatments which can be progressed from the lab bench to the beds of children on wards in our hospitals as quickly as possible. These new treatments are specifically targeting childhood cancers, so we can develop safer and more effective drugs and drug combinations that will minimise side-effects and ultimately give children with cancer the best chance of a cure with the highest possible quality of life.
We are currently leading the establishment of the Zero Childhood Cancer national child cancer personalised medicine program for children with the most aggressive cancers, in partnership with the Sydney Children’s Hospitals Network. This program will revolutionise the way treatment decisions are made, with the aim of improving survivorship for those children at highest risk of treatment failure from their disease.